NCT04301414 - Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

March 13, 2025

Study Completion Date

March 13, 2025

Conditions

Prostate Cancer

Interventions

DRUG

BMS-986218 and Degarelix

BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.

DRUG

Degarelix

Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York